Neoantigens Market is expected to reach US$ 10,54,783.54 Thousand by 2028

Published Date: 17 May 2021

Report : Neoantigens Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Treatment (Combination Therapy and Mono Therapy) and Therapeutic Specialty (Gastrointestinal Cancer, Lung Cancer, Solid Tumor, Urinary Systems Cancers, Melanoma, Head and Neck Cancer, and Others)

Combination Therapy Segment to Drive Neoantigens Market During 2023–2028

 

According to The Insight Partners market research study titled “Neoantigens Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Treatment and Therapeutic Specialty,” the market is expected to reach US$ 10,54,783.54 thousand by 2028 from US$ 2,71,428.57 thousand in 2023. It is estimated to grow at a CAGR of 31.2% from 2023 to 2028. The report highlights the trends prevalent in the market and the factors driving the market along with those that act as deterrents to its growth.

 

Based on treatment, the neoantigens market is segmented into combination therapy and mono therapy. In 2023, combination therapy is estimated to hold a larger share of the market, whereas the mono therapy segment is estimated to grow at a faster CAGR of 33.0%. Growth of the combination therapy segment is attributed to increasing numbers of clinical trials performed with other immunotherapies such as checkpoint inhibitors. Various collaborations are performed by the companies operating in this segment, which is likely to foster the market growth in coming years.

 

The global neoantigens market is driven by developments in neoantigen vaccines against cancer and increasing prevalence of cancer. However, possible side effects associated with neoantigen vaccines are likely to hinder the growth of the neoantigens market.

 

Achilles Therapeutics plc; Advaxis, Inc.; Frame Cancer Therapeutics; Genocea; Gradalis, Inc.; Gritstone Oncology; Immunicum AB; Medigene AG; Ziopharm Oncology, Inc.; and Moderna, Inc. are among the prominent players operating in the neoantigens market. Following are the two identified key players in the market based on their product offering as well as R&D expenditures and developments. The companies have implemented several inorganic strategies to enhance the product development and commercialize their products in the market. For instance, in January 2021, Gradalis confirmed that results from the VITAL clinical trial were released in The Lancet Oncology, demonstrating that Vigil front-line maintenance use was well accepted and resulted in increased recurrence-free survival (RFS) and overall survival (OS) in patients with BRCA1/2 -wt advanced ovarian cancer.

Global Neoantigens Market, by Region, 2023 (%)
Global Neoantigens Market, by Region, 2023 (%)

The report segments the global neoantigens market as follows:

 

By Treatment
  • Combination Therapy
  • Mono Therapy
By Therapeutic Specialty
  • Gastrointestinal Cancer
  • Lung Cancer
  • Solid Tumors
  • Urinary System Cancers
  • Melanoma
  • Head and Neck Cancer
  • Others
By Geography
  • North America
      • US
      • Canada
      • Mexico
  • Europe
      • UK
      • Germany
      • France
      • Italy
      • Spain
      • Rest of Europe
  • Asia Pacific (APAC)
      • Japan
      • China
      • India
      • Australia
      • South Korea
      • Rest of APAC
  • Middle East & Africa (MEA)
      • South Africa
      • UAE
      • Saudi Arabia
      • Rest of MEA
  • South and Central America (SCAM)
      • Brazil
      • Argentina
      • Rest of SCAM

Contact Us
Contact Person: Sameer Joshi 
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com 
Download Free PDF Brochure